Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Net Cash Flow: 2020-2024

Historic Net Cash Flow for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to $33.6 million.

  • Entrada Therapeutics' Net Cash Flow rose 119.41% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 41.77%. This contributed to the annual value of $33.6 million for FY2024, which is 49.74% up from last year.
  • According to the latest figures from FY2024, Entrada Therapeutics' Net Cash Flow is $33.6 million, which was up 49.74% from $22.4 million recorded in FY2023.
  • Entrada Therapeutics' 5-year Net Cash Flow high stood at $252.0 million for FY2021, and its period low was -$242.0 million during FY2022.
  • For the 3-year period, Entrada Therapeutics' Net Cash Flow averaged around -$62.0 million, with its median value being $22.4 million (2023).
  • Its Net Cash Flow has fluctuated over the past 5 years, first spiked by 1,035.17% in 2021, then plummeted by 196.01% in 2022.
  • Yearly analysis of 5 years shows Entrada Therapeutics' Net Cash Flow stood at $22.2 million in 2020, then spiked by 1,035.17% to $252.0 million in 2021, then crashed by 196.01% to -$242.0 million in 2022, then skyrocketed by 109.28% to $22.4 million in 2023, then spiked by 49.74% to $33.6 million in 2024.